Problems with Gabapentin Misuse are a Sign of Improper Prescribing: Report
A new report warns that off-label prescribing is a driving factor behind increasing gabapentin misuse and overdoses.
Tag Archives: Off-Label Marketing
-
-
Bayer Whistleblower Settlement Over Trasylol, Avelox and Baycol Results in $40 Million Payment
Bayer has agreed to pay $40 million to resolve a whistleblower lawsuit which accused it of kickback schemes and off-label marketing of the drugs Avelox, Baycol and Trasylol.
-
Whistleblower Lawsuit Over AstraZeneca Off-Label Marketing Ends in $2.4M Verdict
An Oregon jury wants AstraZeneca to pay $2.4 million for violating a former employee's whistleblower rights after she claimed the company was illegally marketing the asthma drug Symbicort.
-
Most Doctors Say FDA Should Continue To Restrict Off-Label Drug Marketing: Study
A new survey finds that most doctors are against drug companies promoting medications for uses not approved by the FDA.
-
Antidepressant Prescriptions For Non-Approved Indications Often Not Supported By Science: Study
Antidepressants are often prescribed off-label despite a lack of scientific evidence that they work well for uses not approved by the FDA, according to a new study.
-
FDA Issues New Draft Guidance On Medical Product Communications
The FDA has issued a new draft guidance on how medical product manufacturers can add information that is not on the drug's labels to promotions and advertising without misbranding their…
-
Abilify Settlement to Result in $19.5 Payment by Bristol-Myers Squibb
The makers of Abilify have agreed to pay $19.5 million to settle claims by 41 states and D.C. that it illegally marketed the antipsychotic for off-label uses.
-
FDA Weighs Risks, Benefits, Of Relaxing Off-Label Marketing Restrictions
The FDA was urged by industry to relax restrictions on off-label drug marketing at a hearing this week, while critics warned that such a move would endanger patient health and…
-
Lawmakers’ Move To Allow off-Label Marketing Opposed By Public Citizen
A consumer watchdog group is warning that proposed legislation to loosen off-label marketing restrictions for drugs could put patients at risk.
-
Drug Company Settlements On Decline As Enforcement Wanes: Public Citizen Report
A Public Citizen report warns of a steep decline in settlements and financial penalties leveled against drug companies by state and federal agencies in recent years.
